Sotera Health price target raised to $15 from $12 at Barclays

Barclays raised the firm’s price target on Sotera Health (SHC) to $15 from $12 and keeps an Overweight rating on the shares. The business continues its steady recovery with volumes in Steri and Nelson expected to build momentum through the year, the analyst tells investors in a research note. Litigation remains an overhang, the analysts adds, and the firm did not get any material updates on this front. The firm also said that steady and stable is the best way to describe the business and the print.